One of the most popular breast cancer speakers at the 2022 European Society of Medical Oncology Congress in Paris was Privatdozent Oleg Gluz, MD, a senior physician of the Lower Rhine Breast Care Center.
Together with colleagues from the Lower Rhine Breast Care Center and the Munich University Hospital, Dr. Gluz is involved in German research programs aimed at developing therapeutic regimens avoiding the use of chemotherapy.
Studies have shown that in the early stages of breast cancer, pre-operative hormone therapy demonstrates high efficiency. It reduces cancer cell proliferation in hormone-sensitive tumors. Until recently this therapy has proven effective in post-menopausal women. At the Paris congress, Dr. Gluz reported that younger patients can also benefit from it, if ovarian function is suppressed simultaneously.
After 3-4 weeks of hormone suppression in younger women, a tumor tissue volume decrease was observed. Thanks to the recent scientific data and knowledge of tumor tissue markers Dr. Gluts can offer a customized treatment plan for each particular case, which is going to be more targeted than the one based only on the tumor clinical features.
“Optimal therapy for young breast cancer patients has been a major research topic for many years,” - says Dr. Gluz. “I believe that in the near future, at least 40 percent of patients who have not reached menopause will not need chemotherapy, while the effectiveness of treatment will not suffer. Moreover, after the treatment is over, women will be able to become pregnant and bear children.”